Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of two nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin and naproxen. Both agents work by inhibiting cyclo-oxygenase enzymes, which reduces prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Indomethacin is used for conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gouty arthritis, bursitis, tendinitis, and closure of patent ductus arteriosus in premature infants. Naproxen is indicated for similar inflammatory conditions including rheumatoid arthritis and osteoarthritis as well as acute gout and dysmenorrhea. The combination has been studied in coamorphous forms to improve physical stability and dissolution rates compared to the individual drugs alone. However, concomitant use of these two NSAIDs is generally not recommended due to increased risk of serious side effects such as gastrointestinal ulcers or bleeding[1][4][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indomethacin + naproxen.